Sunday, January 03, 2016 2:48:18 PM
The reason this company is CHANGED and most here and sudden massive interest is
WORLDWIDE rights
Now they can get drug approved and sell in many countries on UNMET need - Europe/Latin America/India and others
all they need is basic phase-1 and since the compound works, phase-1 is the easiest things to do..
DO NOT sell below 0.3-0.4
Heading right there
This company can afford have 40-50 million market cap based on worldwide potential
The reason it did not attract interest earlier is USA patent are fine, but FDA approval route is complex and expensive, not possible without big fat pharma. The Pharma companies in USA kill small biotechs using FDA approval complex route, their big money hampers approval process for small bios which die due to lack of funding and coverage, now that's not a problem. With worldwide right the game is now 100% changed
All they need is phase-1 now, that's it..as long as TOXICOLOGY reports are ok and efficacy data with some survival rates - even 2-3 months survival is big number for deadly Pancreatic cancer... With worldwide rights, they don't need to expensive 500 patient and other complex trials with large data sets. By phase-3 it will be too late for a microcap to survive. Now all you need is phase-1
Load up tomorrow AS MUCH AS you can DO NOT Miss..
This is by and far the fastest and easiest ride in microcap.
0.1 will be quick here, Don't even think !!! that puts at par with many PRE-CLINICAL cancer / immunotherapy stocks like PPCH which trade at 14-15 million market
I have studied and invested in many biotechs that are immunotherapy stocks such as JUNO, KITE, BLUE, ADRO, ADXS, PBYI and few -
This will ride all the way to 0.2 without any issues
DO NOT MISS !
Load up as much as you can below 0.05
don't even think !
This is 0.1 MINIMUM stock..I know this immuno and small/micro field too well because I have been investing in this for years. I own all above stocks, biggest holding is JUNO. The biggest money is made up to phase-1/phase-2 in all these stocks, most fail in phase-3, by phase-2 most of them sport 400-500 million market cap. Assuming some dilution I think this could be70-80 cents stock in an year based on multiples and hopefully phase-1 new will push it higher next year, keep in mind phase-1 is the EASIEST part and patented compound has 100 times better in phase-1
so LOAD UP !, IGNORE all the NOISE !
period
WORLDWIDE rights
Now they can get drug approved and sell in many countries on UNMET need - Europe/Latin America/India and others
all they need is basic phase-1 and since the compound works, phase-1 is the easiest things to do..
DO NOT sell below 0.3-0.4
Heading right there
This company can afford have 40-50 million market cap based on worldwide potential
The reason it did not attract interest earlier is USA patent are fine, but FDA approval route is complex and expensive, not possible without big fat pharma. The Pharma companies in USA kill small biotechs using FDA approval complex route, their big money hampers approval process for small bios which die due to lack of funding and coverage, now that's not a problem. With worldwide right the game is now 100% changed
All they need is phase-1 now, that's it..as long as TOXICOLOGY reports are ok and efficacy data with some survival rates - even 2-3 months survival is big number for deadly Pancreatic cancer... With worldwide rights, they don't need to expensive 500 patient and other complex trials with large data sets. By phase-3 it will be too late for a microcap to survive. Now all you need is phase-1
Load up tomorrow AS MUCH AS you can DO NOT Miss..
This is by and far the fastest and easiest ride in microcap.
0.1 will be quick here, Don't even think !!! that puts at par with many PRE-CLINICAL cancer / immunotherapy stocks like PPCH which trade at 14-15 million market
I have studied and invested in many biotechs that are immunotherapy stocks such as JUNO, KITE, BLUE, ADRO, ADXS, PBYI and few -
This will ride all the way to 0.2 without any issues
DO NOT MISS !
Load up as much as you can below 0.05
don't even think !
This is 0.1 MINIMUM stock..I know this immuno and small/micro field too well because I have been investing in this for years. I own all above stocks, biggest holding is JUNO. The biggest money is made up to phase-1/phase-2 in all these stocks, most fail in phase-3, by phase-2 most of them sport 400-500 million market cap. Assuming some dilution I think this could be70-80 cents stock in an year based on multiples and hopefully phase-1 new will push it higher next year, keep in mind phase-1 is the EASIEST part and patented compound has 100 times better in phase-1
so LOAD UP !, IGNORE all the NOISE !
period
Recent SBFM News
- Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year • ACCESS Newswire • 04/06/2026 12:30:00 PM
- Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea • ACCESS Newswire • 10/28/2025 11:45:00 AM
- Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline • ACCESS Newswire • 10/20/2025 11:45:00 AM
- Sunshine Biopharma Launches Cholesterol Fighting Medicine Pravastatin • ACCESS Newswire • 10/16/2025 11:45:00 AM
- Sunshine Biopharma Allocates $5 Million for Investment in Bitcoin as Strategic Reserve Asset to Enhance Treasury Resilience • ACCESS Newswire • 10/14/2025 11:00:00 AM
- Sunshine Biopharma and University of Arizona Develop a Potent New Series of Protease Inhibitors for Treatment of SARS Coronavirus Infections • ACCESS Newswire • 10/09/2025 12:00:00 PM
